Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
Albert Grinshpun, Sara M. Tolaney, Harold J. Burstein, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

Circulating tumor DNA validity and potential uses in metastatic breast cancer
Ottavia Amato, Nefeli Giannopoulou, Michail Ignatiadis
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 17
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Cynthia L. Palmer, Britton Boras, Bernadette Pascual, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 464-481.e14
Open Access | Times Cited: 3
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 6
Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials
Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, et al.
The Breast (2024) Vol. 75, pp. 103729-103729
Open Access | Times Cited: 4
Advancing Treatment Choices: CDK4/6 Inhibitor Switching in HR+/HER2- Metastatic Breast Cancer
Paola Zagami, Angela Espósito, Beatrice Taurelli Salimbeni, et al.
The Breast (2025) Vol. 79, pp. 103875-103875
Open Access
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
Ilenia Migliaccio, Cristina Guarducci, Luca Malorni
Advances in experimental medicine and biology (2025), pp. 475-493
Closed Access
Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer
L. Hohmann, K. Sigurjónsdóttir, Ana Bosch Campos, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions
Fernando Moreno, Vega Iranzo, I. Álvarez, et al.
Clinical & Translational Oncology (2025)
Closed Access
Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review
Nuno Alves, Ana Filipa Duarte, David Fernandes Ribeiro, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Cardiovascular complications of ribociclib in breast cancer patients
Oraianthi Fiste, Evangelos Mavrothalassitis, Kleoniki Apostolidou, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104296-104296
Closed Access | Times Cited: 3
TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma
Shu Chen, Xi Zhang, Basappa Basappa, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access
Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis
Yakup Ergün, Mutlu Doğan, Gökhan Uçar, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 17, pp. 1901-1909
Closed Access | Times Cited: 7
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Natàlia Lorman-Carbó, Olga Martínez‐Sáez, Aranzazu Fernandez-Martinez, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
Joseph J. Zhao, Khi Yung Fong, Yiong Huak Chan, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4558-4558
Open Access | Times Cited: 4
Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer
Neil Carleton, Julia Foldi
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 1
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation
Alison Antoine, David Pérol, Mathieu Robain, et al.
European Journal of Cancer (2024) Vol. 213, pp. 115072-115072
Open Access | Times Cited: 1
CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response
Ting Hong, Anna C Hogger, Dongbiao Wang, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer
Dorian V. Ziegler, Kanishka Parashar, Lluís Fajas
Seminars in Cancer Biology (2023) Vol. 98, pp. 51-63
Open Access | Times Cited: 3
Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
Emilie Adrian Christiansen, Iben Kümler
Future Science OA (2024) Vol. 10, Iss. 1
Open Access
Discovery and Preclinical Evaluations of Tqb3616, a Novel Cdk4-Biased Inhibitor
Charles Z. Ding, Zhaobing Xu, Yingchun Liu, et al.
(2024)
Closed Access
Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis
Marcin Kubeczko, Anna Polakiewicz-Gilowska, K Swiderska, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer
Lis Victória Ravani, Pedro Calomeni, Maysa Vilbert, et al.
JCO Oncology Practice (2024)
Closed Access
Dual Inhibitors of CDK4 /6 for Treating Cancer
Peter L. Toogood
(2024), pp. 319-337
Closed Access
Sacituzumab govitecan: A narrative drug review
Praful Pandey, Ajay Gogia
Cancer Research Statistics and Treatment (2023) Vol. 6, Iss. 4, pp. 562-572
Open Access
Page 1

Scroll to top